{"id":360,"date":"2024-09-26T14:14:10","date_gmt":"2024-09-26T14:14:10","guid":{"rendered":"https:\/\/stgmevpro.wpenginepowered.com\/?page_id=360"},"modified":"2025-09-08T12:43:54","modified_gmt":"2025-09-08T12:43:54","slug":"trial-hcp","status":"publish","type":"page","link":"https:\/\/mevproclinicaltrials.com\/nl-nl\/trial-hcp\/","title":{"rendered":"Trial HCP"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"360\" class=\"elementor elementor-360\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-00e60df header-background e-flex e-con-boxed e-con e-parent\" data-id=\"00e60df\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-37dd70f e-con-full e-flex e-con e-child\" data-id=\"37dd70f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b3cf64b elementor-widget__width-initial elementor-widget-tablet__width-inherit elementor-widget elementor-widget-heading\" data-id=\"b3cf64b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Klinische onderzoeken van Pfizer naar prostaatkanker met MEVPRO<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d8b7b5d hero-heading elementor-widget__width-initial elementor-widget-mobile__width-inherit elementor-widget-tablet__width-inherit elementor-widget elementor-widget-heading\" data-id=\"d8b7b5d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Help het onderzoek naar behandeling van metastatische prostaatkanker te bevorderen<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-28b8308 e-con-full e-flex e-con e-child\" data-id=\"28b8308\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-272fb55 e-flex e-con-boxed e-con e-parent\" data-id=\"272fb55\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-24e7439 elementor-widget elementor-widget-heading\" data-id=\"24e7439\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Ontdek de klinische onderzoeken van Pfizer met MEVPRO als mogelijke opties voor uw pati\u00ebnten<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-357189b4 smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"357189b4\" data-element_type=\"container\" data-e-type=\"container\" id=\"MEVPRO-1\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-564190de e-con-full e-flex e-con e-child\" data-id=\"564190de\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5211ffb1 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5211ffb1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Nog niet op zoek naar deelnemers<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-88646db elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"88646db\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Rekrutering<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1be04a7e textBreast elementor-widget elementor-widget-text-editor\" data-id=\"1be04a7e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-1\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-54b00164 elementor-widget elementor-widget-text-editor\" data-id=\"54b00164\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tVoor uw pati\u00ebnten met abirateron-resistente metastatische prostaatkanker\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-12eb84b2 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"12eb84b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06551324?term=NCT06551324&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1a8227d1 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"1a8227d1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&#038;EUCT=2024-511650-50-00\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7103bdce e-con-full e-flex e-con e-child\" data-id=\"7103bdce\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-31ed7ff5 elementor-widget elementor-widget-image\" data-id=\"31ed7ff5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6e216dc7 elementor-widget elementor-widget-text-editor\" data-id=\"6e216dc7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tEen fase 3 klinisch onderzoek ter evaluatie van het experimentele geneesmiddel (mevrometostat) in combinatie met enzalutamide in vergelijking met alleen enzalutamide of docetaxel bij volwassenen met mCRPC die eerder zijn behandeld met abirateronacetaat.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-59482efa learn-more mevpro1Tile elementor-widget elementor-widget-button\" data-id=\"59482efa\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtn5\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Meer informatie<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6cfadaa8 learn-more mevpro1Tile elementor-widget elementor-widget-button\" data-id=\"6cfadaa8\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtnopen5\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Meer informatie<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6c27029f elementor-widget elementor-widget-html\" data-id=\"6c27029f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn5\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo5\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn5\").style.display = \"none\";\n      document.getElementById(\"morebtnopen5\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen5\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo5\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn5\").style.display = \"block\";\n      document.getElementById(\"morebtnopen5\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7c176cc9 bigtrial e-flex e-con-boxed e-con e-parent\" data-id=\"7c176cc9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-695a13a0 detailsveritac elementor-widget elementor-widget-template\" data-id=\"695a13a0\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"moreinfo5\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"447\" class=\"elementor elementor-447\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tDetails van het onderzoek\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-1 is a Phase 3, randomized, open-label clinical trial to evaluate an investigational medicine called mevrometostat for men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed after treatment with abiraterone acetate. MEVPRO-1 will investigate whether mevrometostat in combination with enzalutamide is superior to either enzalutamide or docetaxel in prolonging radiographic progression-free survival in the mCRPC setting.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tApproximately 600 participants will be randomly assigned in a 1:1 ratio to Arm A or Arm B.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c925d11 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c925d11\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c3b9a9a e-con-full e-flex e-con e-child\" data-id=\"2c3b9a9a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80db81b elementor-widget elementor-widget-text-editor\" data-id=\"80db81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Onderzoeksgroep A: <\/span><br>Mevrometostat 875 mg BID <span style=\"font-weight: 600;\">plus<\/span><br> 160 mg enzalutamide QD<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-25fdc07 e-con-full e-flex e-con e-child\" data-id=\"25fdc07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d6e223f elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6e223f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><span style=\"color: #097900; font-weight: 600;\">Vergelijkingsgroep B:<br> <\/span><br \/>De onderzoeksarts kiest voor enzalutamide 160 mg QD <span style=\"font-weight: 600;\">OF<\/span><br \/>docetaxel 75 mg\/m<sup>2<\/sup> IV elke cyclus (21 dagen) gedurende maximaal 10 cycli.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tDeelnemers krijgen een experimentele behandeling tot radiografische ziekteprogressie, onaanvaardbare toxiciteit, protocolschending, terugtrekking of be\u00ebindiging van het onderzoek. De duur van deelname aan MEVPRO-1 varieert afhankelijk van hoe goed deelnemers de onderzoeksbehandeling verdragen of de tijd tot ziekteprogressie. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe study includes a 28-day screening period, the treatment period, and a 28- to 35-day safety follow-up. The treatment period in the study will consist of cycles of 3 weeks (docetaxel group) or 4 weeks (enzalutamide groups). Participants receiving investigational mevrometostat and enzalutamide or enzalutamide alone will attend 2 study visits in Cycles 1 and 2, then 1 study visit per cycle thereafter. Participants receiving standard-of-care docetaxel will attend 1 study visit per cycle for up to 10 cycles. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLong-term safety follow-up will consist of visits every 12 weeks from the last dose until the study is complete, which may take many years, or until the participant withdraws consent.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tGeschiktheid van deelnemers \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Belangrijkste inclusiecriteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Mannelijke deelnemers \u2265 18 jaar bij de screening.\n<\/li>\n \t<li>Histologisch of cytologisch bevestigd adenocarcinoom van de prostaat zonder kleincellige kenmerken. \n<\/li>\n\n \t<li>Uitgezaaide ziekte in bot gedocumenteerd op een botscan of in zacht weefsel gedocumenteerd op een CT-\/MRI-scan. \n<\/li>\n \t<li>Evidence of disease progression on or after treatment with at least 12 weeks of abiraterone acetate in the metastatic castration-sensitive prostate (mCSPC) cancer or first-line mCRPC setting.\n<\/li>\n\n\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Belangrijkste exclusiecriteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Treatment with chemotherapy since becoming castration-resistant.\n<\/li>\n \t<li>Voorgeschiedenis van andere kanker in de afgelopen 3 jaar (met uitzondering van bepaalde huidkankers of kanker in een vroeg stadium die is genezen).\n<\/li>\n \t<li>Klinisch significante cardiovasculaire ziekte, nierziekte of leverziekte.\n<\/li>\n \t<li>Eerdere behandeling voor prostaatkanker in een willekeurig stadium met cytotoxische chemotherapie, radioligandtherapie, ARSi (waaronder enzalutamide, apalutamide, darlutamide), PARP-monotherapie of een andere systemische behandeling tegen kanker.\n<\/li>\n \t<li>Ingrijpende operatie of palliatieve gelokaliseerde bestralingstherapie binnen 14 dagen v\u00f3\u00f3r randomisatie.\n<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Neem contact op met het onderzoeksteam of een Field Medical-vertegenwoordiger van Pfizer voor de volledige geschiktheidscriteria.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<span style=\"font-weight: 600;\">Hartelijk dank dat u dit klinisch onderzoek voor uw pati\u00ebnten overweegt.<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-1\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c3ac92f elementor-widget elementor-widget-html\" data-id=\"3c3ac92f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.addEventListener(\"DOMContentLoaded\", function() {\n      document.getElementById(\"closebtn\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n  \n      document.getElementById(\"morebtnopen\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n    });\n  <\/script>\n  \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4d6b27e1 smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"4d6b27e1\" data-element_type=\"container\" data-e-type=\"container\" id=\"MEVPRO-2\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-7e5f1952 e-con-full e-flex e-con e-child\" data-id=\"7e5f1952\" data-element_type=\"container\" data-e-type=\"container\" id=\"tactiveugov\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6939f0d0 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"6939f0d0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Nog niet op zoek naar deelnemers<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d1cd2fd elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"d1cd2fd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Rekrutering<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b223d4f textBreast elementor-widget elementor-widget-text-editor\" data-id=\"b223d4f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-2\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-24d09b05 elementor-widget elementor-widget-text-editor\" data-id=\"24d09b05\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tVoor uw pati\u00ebnten die geen hormonale therapie of chemotherapie hebben geprobeerd voor uitgezaaide castratieresistente prostaatkanker\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2880ba5a elementor-align-left elementor-widget elementor-widget-button\" data-id=\"2880ba5a\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"govtactive\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06629779?term=NCT06629779%20&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3075cce8 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"3075cce8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&#038;EUCT=2024-511652-40-00\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1b8f53e e-con-full e-flex e-con e-child\" data-id=\"1b8f53e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-52ca76b6 elementor-widget elementor-widget-image\" data-id=\"52ca76b6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2f482ba8 elementor-widget elementor-widget-text-editor\" data-id=\"2f482ba8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tEen fase 3 klinisch onderzoek ter evaluatie van het experimentele geneesmiddel (mevrometostat) in combinatie met enzalutamide in vergelijking met een placebo in combinatie met enzalutamide bij volwassenen met mCRPC die geen hormonale therapie of chemotherapie hebben geprobeerd in een castratieresistente setting. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bcc563d learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"bcc563d\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtn4\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Meer informatie<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-41caf536 learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"41caf536\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtnopen3\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Meer informatie<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-355fbbde elementor-widget elementor-widget-html\" data-id=\"355fbbde\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn4\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo4\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn4\").style.display = \"none\";\n      document.getElementById(\"morebtnopen3\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen3\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo4\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn4\").style.display = \"block\";\n      document.getElementById(\"morebtnopen3\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2f15f81b bigtrial2 e-flex e-con-boxed e-con e-parent\" data-id=\"2f15f81b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-58d9eadb detailsveritac elementor-widget elementor-widget-template\" data-id=\"58d9eadb\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"moreinfo4\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"457\" class=\"elementor elementor-457\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tDetails van het onderzoek\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-2 is a Phase 3, randomized, double-blind clinical trial of an investigational medicine called mevrometostat in combination with enzalutamide compared to a placebo in combination with enzalutamide in adults with mCRPC (metastatic castration resistant prostate cancer). \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-912f2e9 elementor-widget elementor-widget-text-editor\" data-id=\"912f2e9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tTijdens MEVPRO-2 zal onderzocht worden of mevrometostat plus enzalutamide anti-androgeenresistentie kan vertragen of voorkomen om een superieur klinisch voordeel te bieden in vergelijking met enzalutamide alleen bij deelnemers met mCRPC die geen hormonale therapie of chemotherapie hebben geprobeerd in de castratieresistente setting.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tOngeveer 900 deelnemers worden willekeurig in een verhouding van 1:1 toegewezen aan groep A of groep B.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c925d11 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c925d11\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c3b9a9a e-con-full e-flex e-con e-child\" data-id=\"2c3b9a9a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80db81b elementor-widget elementor-widget-text-editor\" data-id=\"80db81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><span style=\"color: #097900; font-weight: 600;\">Onderzoeksgroep A: <\/span><br \/>Mevrometostat 875 mg BID <span style=\"font-weight: 600;\">plus<\/span><br \/>160 mg enzalutamide<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-25fdc07 e-con-full e-flex e-con e-child\" data-id=\"25fdc07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d6e223f elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6e223f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Vergelijkingsgroep B:<br> <\/span><br>\nPlacebotabletten BID <span style=\"font-weight: 600;\">plus<\/span>\n160 mg enzalutamide QD<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tDeelnemers krijgen een experimentele behandeling tot radiografische ziekteprogressie, onaanvaardbare toxiciteit, protocolschending, terugtrekking of be\u00ebindiging van het onderzoek. De duur van deelname aan MEVPRO-2 varieert afhankelijk van hoe goed deelnemers de onderzoeksbehandeling verdragen of de tijd tot ziekteprogressie. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe study includes a 28-day screening period, the treatment period, and a 28 to 35-day safety follow-up. The treatment period in the study will consist of cycles every 28 days. Participants will attend visits every 2 weeks until week 9, then every 4 weeks until week 53, and then every 8 weeks while receiving the study medicine. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLong-term safety follow-up will consist of visits every 12 weeks from the last dose until the study is complete, which may take many years, or until the participant withdraws consent.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tGeschiktheid van deelnemers \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Belangrijkste inclusiecriteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Mannelijke deelnemers \u2265 18 jaar bij de screening.\n<\/li>\n \t<li>Histologisch of cytologisch bevestigd adenocarcinoom van de prostaat zonder kleincellige kenmerken.<\/li>\n \t<li>Uitgezaaide ziekte in bot gedocumenteerd op een botscan of in zacht weefsel gedocumenteerd op een CT-\/MRI-scan.\u00a0<\/li>\n \t<li>Progressieve ziekte in het geval van medische of chirurgische castratie zoals gedefinieerd door te voldoen aan 1\u202fof meer van de volgende 3\u202fcriteria:<ul><li>PSA progression defined by a minimum of two rising PSA levels with an interval of \u22651 week between each determination, with a PSA value at the Screening visit being \u22652 \u03bcg\/L.<\/li>\n<li>Ziekteprogressie van zacht weefsel zoals gedefinieerd door RECIST 1.1.<\/li>\n<li>Progressie van botziekte gedefinieerd door PCWG3 met 2 of meer nieuwe metastatische botlaesies op een radionuclide-botscan van het hele lichaam.<\/li><\/ul><\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Belangrijkste exclusiecriteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Participants must be treatment na\u00efve at the mCRPC stage, e.g., participants cannot have received any cytotoxic chemotherapy (includes but not limited to docetaxel), received ARSI\/ abiraterone acetate in mCRPC, mCSPC or non-metastatic PC. Prior docetaxel in mCSPC is allowed.\n<\/li>\n \t<li>Voorgeschiedenis van andere kanker in de afgelopen 3 jaar (met uitzondering van bepaalde huidkankers of kanker in een vroeg stadium die is genezen).\n<\/li>\n \t<li>Klinisch significante cardiovasculaire ziekte, nierziekte of leverziekte.\n<\/li>\n \t<li>Eerdere behandeling voor prostaatkanker in een willekeurig stadium met cytotoxische chemotherapie, radioligandtherapie, ARSi (waaronder enzalutamide, apalutamide, darlutamide), PARP-monotherapie of een andere systemische behandeling tegen kanker.\n<\/li>\n \t<li>Ingrijpende operatie of palliatieve gelokaliseerde bestralingstherapie binnen 14 dagen v\u00f3\u00f3r randomisatie.\n<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Neem contact op met het onderzoeksteam of een Field Medical-vertegenwoordiger van Pfizer voor de volledige geschiktheidscriteria.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 600;\">Hartelijk dank dat u dit klinisch onderzoek voor uw pati\u00ebnten overweegt.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-2\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c3ac92f elementor-widget elementor-widget-html\" data-id=\"3c3ac92f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.addEventListener(\"DOMContentLoaded\", function() {\n      document.getElementById(\"closebtn\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n  \n      document.getElementById(\"morebtnopen\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n    });\n  <\/script>\n  \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-26605ec smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"26605ec\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a2359a5 e-con-full e-flex e-con e-child\" data-id=\"a2359a5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bef1867 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"bef1867\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Nog niet op zoek naar deelnemers<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-88680b2 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"88680b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Rekrutering<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-15edc24 textBreast elementor-widget elementor-widget-text-editor\" data-id=\"15edc24\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-3 \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f196d8d elementor-widget elementor-widget-text-editor\" data-id=\"f196d8d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tVoor uw pati\u00ebnten met metastatische, castratiegevoelige prostaatkanker die niet zijn behandeld voor hun castratiegevoelige kanker, met uitzondering van androgeendeprivatietherapie (chemisch of chirurgisch) \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-47889f4 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"47889f4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-733b478 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"733b478\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-71c0648 e-con-full e-flex e-con e-child\" data-id=\"71c0648\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d7e84ba elementor-widget elementor-widget-image\" data-id=\"d7e84ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d83ebaf elementor-widget elementor-widget-text-editor\" data-id=\"d83ebaf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Een fase 3 klinisch onderzoek ter evaluatie van het onderzoeksmiddel (mevrometostat) in combinatie met enzalutamide in vergelijking met een placebo in combinatie met enzalutamide bij volwassenen met nog niet eerder behandelde mCSPC.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-117c6c3 learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"117c6c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Meer informatie<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-92fbfab learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"92fbfab\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Meer informatie<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0287610 elementor-widget elementor-widget-html\" data-id=\"0287610\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn6\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo55\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn6\").style.display = \"none\";\n      document.getElementById(\"morebtnopen4\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen4\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo55\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn6\").style.display = \"block\";\n      document.getElementById(\"morebtnopen4\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1118ae3 bigtrial2 e-flex e-con-boxed e-con e-parent\" data-id=\"1118ae3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3a0e637 detailsveritac elementor-widget elementor-widget-template\" data-id=\"3a0e637\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"587\" class=\"elementor elementor-587\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tDetails van het onderzoek\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-3 is een fase 3, gerandomiseerd, dubbelblind klinisch onderzoek naar een experimenteel geneesmiddel genaamd mevrometostat in combinatie met enzalutamide in vergelijking met een placebo in combinatie met enzalutamide bij volwassenen met mCSPC (metastatische castratiegevoelige prostaatkanker).\u00a0\u00a0\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-912f2e9 elementor-widget elementor-widget-text-editor\" data-id=\"912f2e9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Tijdens MEVPRO-3 zal onderzocht worden of mevrometostat plus enzalutamide anti-androgeenresistentie kan vertragen of voorkomen om een superieur klinisch voordeel te bieden in vergelijking met placebo plus enzalutamide bij deelnemers met mCSPC die geen nieuwe hormonale therapie of chemotherapie hebben geprobeerd in de castratiegevoelige setting.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tOngeveer 1000 deelnemers worden willekeurig in een verhouding van 1:1 toegewezen aan groep A of groep B.\u00a0\u00a0\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-72d6815 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"72d6815\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-01585a6 e-con-full e-flex e-con e-child\" data-id=\"01585a6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fb5fdd3 elementor-widget elementor-widget-text-editor\" data-id=\"fb5fdd3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><span style=\"color: #097900; font-weight: 600;\">Onderzoeksgroep A: <\/span><br \/>875\u202fmg mevrometostat tweemaal daags (BID)<br \/><span style=\"font-weight: 600;\">plus<\/span> 160\u202fmg enzalutamide eenmaal daags (QD)<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0db97de e-con-full e-flex e-con e-child\" data-id=\"0db97de\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-18329b8 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"18329b8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><span style=\"color: #097900; font-weight: 600;\">Controlegroep B: <\/span><br \/>Placebotabletten BID <span style=\"font-weight: 600;\">plus<\/span><br \/>enzalutamide 160 mg QD<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Deelnemers krijgen een experimentele behandeling tot radiografische ziekteprogressie, onaanvaardbare toxiciteit, protocolschending, terugtrekking of be\u00ebindiging van het onderzoek. De duur van deelname aan MEVPRO-3 varieert afhankelijk van hoe goed deelnemers de onderzoeksbehandeling verdragen of de tijd tot ziekteprogressie.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tHet onderzoek omvat een screeningsperiode van 28 dagen, de behandelingsperiode, een veiligheidsfollow-up van 28 tot 35 dagen en een langdurige follow-upperiode.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tDe behandelingsperiode van het onderzoek bestaat uit cycli om de 4\u202fweken (28 dagen). Deelnemers zullen elke 4\u202fweken bezoeken bijwonen tot cyclus\u202f14 en vervolgens elke 8\u202fweken terwijl ze het onderzoeksmiddel ontvangen. Deelnemers krijgen elke 8 weken beeldvormingsevaluaties tot week\u202f25, daarna elke 12\u202fweken.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d537eca elementor-widget elementor-widget-text-editor\" data-id=\"d537eca\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>De veiligheidsfollow-up op de lange termijn bestaat uit bezoeken om de 8\u202fweken tot week\u202f25 en vervolgens elke 12\u202fweken tot het onderzoek is afgerond, wat vele jaren kan duren of tot de deelnemer hun toestemming intrekt.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tGeschiktheid van deelnemers \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Belangrijkste inclusiecriteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Mannelijke deelnemers \u2265 18 jaar bij de screening.<\/li><li>Histologisch of cytologisch bevestigd adenocarcinoom van de prostaat zonder kleincellige kenmerken.<\/li><li class=\"update-delete\">Uitgezaaide ziekte in bot gedocumenteerd op een botscan of in zacht weefsel gedocumenteerd op een CT-\/MRI-scan.<\/li><li>Metastatische prostaatkanker gedocumenteerd door een positieve botscan (voor botziekte) of metastatische laesie(s) op een CT- of MRI-scan (voor wekedelen-\/viscerale ziekte).\u202f<br \/><ul class=\"full-dot\"><li>Meetbare wekedelen-\/viscerale ziekte (volgens RECIST v1.1) is vereist als er geen evalueerbare botlaesie is (volgens PCWG3-criteria).<\/li><li>Alleen voor deelnemers met meetbare wekedelenziekte is regionale lymfeklierziekte (bijv. onder aortabifurcatie) niet voldoende om de deelnemer in aanmerking te doen komen voor deelname aan het onderzoek.<\/li><li>PET en SPECT zijn geen evalueerbare beeldvormingsmodaliteiten voor dit onderzoek.<\/li><li>Een botscan met intense symmetrische activiteit in de botten (ook wel superscan genoemd) wordt niet als evalueerbaar beschouwd.<\/li><\/ul><\/li><li>Deelnemers moeten ECOG PS 0 of 1 hebben.<\/li><li>Deelnemers mogen geen cytotoxische chemotherapie, ARPI's (bijv. enzalutamide, apalutamide, abirateronacetaat of darolutamide) hebben ontvangen, of andere systemische antikankerbehandelingen voor mCSPC, met de volgende uitzonderingen:<br \/><ul class=\"full-dot\"><li>ADT (chemisch of chirurgisch) moet voorafgaand aan randomisatie worden gestart en moet gedurende het onderzoek worden voortgezet. Eerdere behandeling met maximaal 3 maanden ADT (met of zonder antiandrogenen) is toegestaan zonder radiografisch bewijs van ziekteprogressie of stijgende PSA-waarden voorafgaand aan dag 1.<\/li><li>Behandeling met oestrogenen, cyproteronacetaat of eerste-generatie antiandrogenen is toegestaan tot randomisatie, maar moet v\u00f3\u00f3r randomisatie worden stopgezet.<\/li><li>Deelnemers kunnen 1\u202fkuur palliatieve bestraling of operatie hebben ondergaan voor symptoombeheer secundair aan prostaatkanker, die ten minste 2\u202fweken voorafgaand aan randomisatie moet zijn afgerond.<br \/>Opmerking: Radicale prostatectomie of definitieve radiotherapie van de primaire prostaattumor voor mCSPC met curatieve intentie is niet toegestaan.<\/li><\/ul><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ffec70a elementor-widget elementor-widget-text-editor\" data-id=\"ffec70a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-ffec70a{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Belangrijkste exclusiecriteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-39687a30{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2efc049 elementor-widget elementor-widget-text-editor\" data-id=\"2efc049\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-2efc049{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-51ce9c7 elementor-widget elementor-widget-text-editor\" data-id=\"51ce9c7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-51ce9c7{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6dbcba0 elementor-widget elementor-widget-text-editor\" data-id=\"6dbcba0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-6dbcba0{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-73e39f3 elementor-widget elementor-widget-text-editor\" data-id=\"73e39f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Eerdere behandeling met:<br \/><ul class=\"full-dot\"><li>ADT in de adjuvante\/neoadjuvante setting, waarbij de voltooiing van ADT &lt;\u202f12\u202fmaanden v\u00f3\u00f3r randomisatie was en de totale duur van ADT &gt;\u202f36\u202fmaanden was.<\/li><li>ARPI's zoals abirateron, apalutamide, darlutamide, enzalutamide of andere experimentele ARPI's.<\/li><li>Cytochroom P17-enzymremmers zoals orale ketoconazol als antikankerbehandelingen voor prostaatkanker.<\/li><li>Chemotherapie inclusief docetaxel of immunotherapie voor prostaatkanker.<\/li><li>Radiofarmaceutica (bijv. 177Lu-PSMA-617, radium-223).<\/li><li>CDK4\/6-remmers.<\/li><li>Een andere antikankerbehandeling voor metastatische prostaatkanker, met uitzondering van palliatieve radiotherapie\/chirurgie en ADT, zoals hierboven besproken.<\/li><\/ul><\/li><li>Voorgeschiedenis van andere kanker in de afgelopen 3 jaar (met uitzondering van bepaalde huidkankers of kanker in een vroeg stadium die is genezen).<\/li><li>Klinisch significante cardiovasculaire ziekte, nierziekte of leverziekte.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bbaac08 elementor-widget elementor-widget-text-editor\" data-id=\"bbaac08\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Eerdere behandeling met:<br \/><ul class=\"full-dot\"><li>ADT in the adjuvant\/neoadjuvant setting, where the completion of ADT was &lt;12 months prior to randomisation and the total duration of ADT was &gt;36 months.<\/li><li>ARPI's zoals abirateron, apalutamide, darlutamide, enzalutamide of andere experimentele ARPI's.<\/li><li>Cytochroom P17-enzymremmers zoals orale ketoconazol als antikankerbehandelingen voor prostaatkanker.<\/li><li>Chemotherapie inclusief docetaxel of immunotherapie voor prostaatkanker.<\/li><li>Radiofarmaceutica (bijv. 177Lu-PSMA-617, radium-223).<\/li><li>CDK4\/6-remmers.<\/li><li>Een andere antikankerbehandeling voor metastatische prostaatkanker, met uitzondering van palliatieve radiotherapie\/chirurgie en ADT, zoals hierboven besproken.<\/li><\/ul><\/li><li>Voorgeschiedenis van andere kanker in de afgelopen 3 jaar (met uitzondering van bepaalde huidkankers of kanker in een vroeg stadium die is genezen).<\/li><li>Klinisch significante cardiovasculaire ziekte, nierziekte of leverziekte.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Neem contact op met het onderzoeksteam of een Field Medical-vertegenwoordiger van Pfizer voor de volledige geschiktheidscriteria.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 600;\">Hartelijk dank dat u dit klinisch onderzoek voor uw pati\u00ebnten overweegt.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-3\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5958faa e-flex e-con-boxed e-con e-parent\" data-id=\"5958faa\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a2b556e e-con-full e-flex e-con e-child\" data-id=\"a2b556e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-03d3426 elementor-widget elementor-widget-heading\" data-id=\"03d3426\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Behandelt u pati\u00ebnten met uitgezaaide prostaatkanker?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1a9e3e1 e-con-full e-flex e-con e-child\" data-id=\"1a9e3e1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-80251c2 e-con-full e-flex e-con e-child\" data-id=\"80251c2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-24624e5 elementor-widget elementor-widget-image\" data-id=\"24624e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"77\" height=\"98\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/medical-record-1.svg\" class=\"attachment-full size-full wp-image-455\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-151dd15 e-con-full e-flex e-con e-child\" data-id=\"151dd15\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-095411b elementor-widget elementor-widget-text-editor\" data-id=\"095411b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tTo learn more about Pfizer\u2019s MEVPRO Prostate Cancer Clinical Trials and how to refer potentially eligible patients, please complete the Contact Form and a member of the Pfizer Field Medical team will contact you. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dc65bb3 elementor-widget elementor-widget-button\" data-id=\"dc65bb3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/nl-nl\/hcp\/#contactform\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Contact Form<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-00be4aa e-flex e-con-boxed e-con e-parent\" data-id=\"00be4aa\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-21c39cd elementor-widget elementor-widget-heading\" data-id=\"21c39cd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Bedankt dat u de klinische onderzoeken van Pfizer naar prostaatkanker met MEVPRO voor uw pati\u00ebnten overweegt.  <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b188a5f e-flex e-con-boxed e-con e-parent\" data-id=\"b188a5f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-11a6f1c e-con-full e-flex e-con e-child\" data-id=\"11a6f1c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d60c0ec elementor-widget elementor-widget-text-editor\" data-id=\"d60c0ec\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Hoe klinische onderzoeken in hun werk gaan<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6bfe395 elementor-widget elementor-widget-image\" data-id=\"6bfe395\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/nl-nl\/clinical-trials\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-572cd84 e-con-full e-flex e-con e-child\" data-id=\"572cd84\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-53bbb16 elementor-widget elementor-widget-text-editor\" data-id=\"53bbb16\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tStappen voor deelname aan een klinisch onderzoek\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a2e0214 elementor-widget elementor-widget-image\" data-id=\"a2e0214\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/nl-nl\/steps-to-join\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-87bed07 e-con-full e-flex e-con e-child\" data-id=\"87bed07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-94f0d2f elementor-widget elementor-widget-text-editor\" data-id=\"94f0d2f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tUw veiligheid en privacy beschermen\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2b7ca47 elementor-widget elementor-widget-image\" data-id=\"2b7ca47\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/nl-nl\/privacy\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b20ecc1 e-con-full e-flex e-con e-child\" data-id=\"b20ecc1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e92688e elementor-widget-tablet__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"e92688e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tVeelgestelde vragen\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-61b0a47 elementor-widget elementor-widget-image\" data-id=\"61b0a47\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/nl-nl\/faq\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Pfizer MEVPRO Prostate Cancer Clinical Trials Help advance metastatic prostate cancer treatment research Explore Pfizer\u2019s MEVPRO Clinical Trials as potential options for your patients Not yet recruiting Recruiting MEVPRO-1For your patients with abiraterone-resistant metastatic prostate cancer Clinicaltrials.gov Clinicaltrialsregister.eu A Phase 3 clinical trial evaluating the investigational medicine (mevrometostat) in combination with enzalutamide compared to enzalutamide [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"single_temp_hcp_trial.php","meta":{"footnotes":""},"class_list":["post-360","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/mevproclinicaltrials.com\/nl-nl\/wp-json\/wp\/v2\/pages\/360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mevproclinicaltrials.com\/nl-nl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mevproclinicaltrials.com\/nl-nl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mevproclinicaltrials.com\/nl-nl\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mevproclinicaltrials.com\/nl-nl\/wp-json\/wp\/v2\/comments?post=360"}],"version-history":[{"count":0,"href":"https:\/\/mevproclinicaltrials.com\/nl-nl\/wp-json\/wp\/v2\/pages\/360\/revisions"}],"wp:attachment":[{"href":"https:\/\/mevproclinicaltrials.com\/nl-nl\/wp-json\/wp\/v2\/media?parent=360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}